# EDGAR Filing Document

**Accession Number:** 0001873835
**File Stem:** 0001493152-25-025182
**Filing Date:** 2025-11
**Character Count:** 6771
**Document Hash:** 9b740f45990ab19daaa7da02b95a9091
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-025182.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001493152-25-025182

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251126

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immix Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001873835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 454869378
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41159
- **FILM NUMBER:** 251531393

**BUSINESS ADDRESS:**
- **STREET 1:** 11400 WEST OLYMPIC BLVD.
- **STREET 2:** SUITE 200
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** (888) 958-1084

**MAIL ADDRESS:**
- **STREET 1:** 10573 W. PICO BLVD.
- **STREET 2:** #58
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): November 26, 2025**

**IMMIX BIOPHARMA, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41159** | **45-4869378** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**11400 West Olympic Blvd., Suite 200**

**Los Angeles, CA 90064**

(Address of principal executive offices)

**(310) 651-8041**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(b)of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value of $0.0001 per share | IMMX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

This Current Report on Form 8-K is being filed solely to file newly dated consents of KMJ Corbin & Company LLP, formerly the independent registered public accounting firm of Immix Biopharma, Inc. (the "<u>Company</u>"), and Crowe LLP, currently the independent registered accounting firm of the Company, each dated November 26, 2025, to the incorporation by reference of their reports dated March 29, 2024, and March 24, 2025, respectively, relating to the consolidated financial statements of the Company included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the "<u>Form 10-K</u>") filed with the Securities and Exchange Commission on March 25, 2025, into the Company's Registration Statement on Form S-3 (No. 333-290725)(the "<u>Registration Statement</u>"), as well as the reference to each of KMJ Corbin & Company LLP and Crowe LLP, under the heading "<u>Experts</u>" in the prospectus included as part of the Registration Statement. The updated consents discussed above are filed as <u>Exhibits 23.2</u> and <u>23.1</u> hereto, respectively, and are incorporated by reference into this <u>Item 8.01</u>.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits**.

---

| | |
|:---|:---|
| **Number** | **Description** |
| 23.1 | [Consent of Crowe LLP](ex23-1.htm) |
| 23.2 | [Consent of KMJ Corbin & Company LLP](ex23-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **Immix Biopharma, Inc.** |
| Dated: November 26, 2025 | */s/ Ilya Rachman* |
|  | Ilya Rachman, Ph.D., M.D. |
|  | Chief Executive Officer |

---

## Exhibit 23.1

**<br> Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference into the Registration Statement on Form S-3 (No. 333-290725) of Immix Biopharma, Inc. of our report dated March 24, 2025 on the consolidated balance sheet of Immix Biopharma, Inc. as of December 31, 2024 and the consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for the year ended December 31, 2024, appearing in the Annual Report on Form 10-K of Immix Biopharma, Inc. for the year ended December 31, 2024, and the reference to us under the heading "Experts" in the prospectus.

*/s/ Crowe LLP*

Los Angeles, California

November 26, 2025

## Exhibit 23.2

**Exhibit 23.2**

<u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT</u>

We consent to the incorporation by reference in the Registration Statement on Form S-3 (File Number 333-290725) of Immix Biopharma, Inc. of our report dated March 29, 2024 relating to the consolidated financial statements of Immix Biopharma, Inc. and its subsidiaries as of and for the year ended December 31, 2023, appearing in the Annual Report on Form 10-K of Immix Biopharma, Inc. for the year ended December 31, 2024. We also consent to the reference to us under the headings "Experts" in the prospectus, which is part of such Registration Statement.

*/s/ KMJ Corbin & Company LLP*

KMJ Corbin & Company LLP

Glendora, California

November 26, 2025